April 17th 2024- Prof. Nigel Russell- Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations
By efrat|2024-04-14T09:41:37+00:00April 16th, 2024|All|Comments Off on April 17th 2024- Prof. Nigel Russell- Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations
About the Author: efrat
Related Posts
July 7th 2024- Dr. Anand Patel- Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era
July 7th 2024- Dr. Anand Patel- Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era
June 24th 2024- Dr. Tamar Tadmor- Supplement of Vitamin D for early-stage Chronic Lymphocytic Leukemia Patients is Associated with a Longer Time to first Treatment